课题基金 / 基金详情

CATHETER-RELATED INFECTIONS IN PEDIATRIC DIALYSIS PATIENTS: POTENTIAL ROLE OF

CATHETER-RELATED INFECTIONS IN PEDIATRIC DIALYSIS PATIENTS: POTENTIAL ROLE OF
小儿透析患者导管相关感染:潜在作用
批准号:
7719251
负责人:
HOWARD TRACHTMAN
金额:
$0.55万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-22 至 2009-03-31

项目摘要

项目成果

HOWARD TRACHTMAN的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 患有终末期肾病(ESRD)的儿童和青少年需要通过经皮途径设备进行透析,容易发生严重的细菌感染,包括导管相关性败血症。我们对导致透析患者发生导管相关感染的宿主因素的理解存在相当大的差距。ESRD患者的单核/巨噬细胞功能紊乱已有文献记载。该项目将测试以下假设:血浆趋化因子水平和细胞相关趋化因子受体的异常会导致巨噬细胞功能减弱,增加发生严重细菌感染(如导管相关性败血症)的风险,对治疗的反应减弱,以及透析患者的反复感染。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Children and adolescents with end stage renal disease (ESRD) who require dialysis through percutaneous access devices are susceptible to serious bacterial infections including catheter-related sepsis. There are considerable gaps in our understanding of the host factors that predispose patients on dialysis to develop catheter-related infections. Disturbances in monocyte/macrophage function have been documented in patients with ESRD. This project will test the hypothesis that abnormalities in plasma chemokine levels and cell-associated chemokine receptors result in diminished macrophage function, heightened risk of developing serious bacterial infections such as catheter-related sepsis, impaired response to treatment, and recurrent infection in pediatric patients on dialysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developmental Origins of Kidney Function in Early Life and Environmental Risks
Environmental Oxidant Stressors in Pediatric Chronic Kidney Disease - Resubmissio
CLINICAL TRIAL: TREATMENT WITH (F6-3019) FOR FOCAL GLOMERULOSCLEROSIS
TREATMENT WITH HUMAN MONOCLONAL ANTIBODY TO CONNECTIVE TISSUE GROWTH FACTOR (FG-
海外基金